>> interim was somewhat confounding given pbo+statin arm also showed regression. Will be interesting to see if that holds with complete data. <<
Patients in the placebo arm probably took their background meds more consistently during the trial than they had taken them before enrolling. This in itself could account for much of the observed placebo response --and part of the response in the 1067 arm.
Market Data 
Markets 
AI
